Product Description
Peramivir (BioCryst Pharmaceuticals) is a novel investigational intravenous neuraminidase inhibitor that exhibits potent antiviral activity against influenza A and B viruses. Peramivir is created by a structure-based drug design and consists of a cyclopentane backbone with a positively charged guanidinyl group and lipophilic side chains. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/22339187/)
Mechanisms of Action: NEU Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous, Inhalant
FDA Designation: *
Approval Status: Approved
Approved Countries: Australia | Belgium | Canada | European Medicines Agency | Germany | Hungary | Ireland | Italy | Japan | Korea | Lithuania | Poland | Portugal | Sweden | Taiwan | United States
Approved Indications: None
Known Adverse Events: None
Company: BioCryst
Company Location: Eastern America
Company Founding Year: 1986
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 8
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Influenza, Human
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20242199 |
CTR20242199 | P1 |
Completed |
Influenza, Human |
2025-01-21 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20244027 |
CTR20244027 | P1 |
Completed |
Influenza, Human |
2025-01-20 |
2025-06-17 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20230741 |
CTR20230741 | P1 |
Completed |
Influenza, Human |
2023-07-07 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20244190 |
CTR20244190 | P1 |
Active, not recruiting |
Influenza, Human |
None |
2025-06-12 |
Start Date|Treatments|Trial Status |
|
CTR20233494 |
CTR20233494 | P2 |
Completed |
Influenza, Human |
2024-01-05 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20252729 |
CTR20252729 | P2 |
Recruiting |
Influenza, Human |
None |
2025-10-05 |
Patient Enrollment|Treatments|Trial Status |
|
CTR20131182 |
CTR20131182 | P3 |
Recruiting |
Influenza, Human |
None |
2025-04-29 |
Treatments |
|
CTR20131184 |
CTR20131184 | P3 |
Recruiting |
Influenza, Human |
None |
2025-04-29 |
Treatments |